Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Total Assets
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) holds total assets worth CN¥4.48 Billion CNY (≈ $655.46 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Jiangxi Fushine Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Jiangxi Fushine Pharmaceutical Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore 300497 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Jiangxi Fushine Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Jiangxi Fushine Pharmaceutical Co Ltd's total assets of CN¥4.48 Billion consist of 33.2% current assets and 66.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.0% |
| Accounts Receivable | CN¥370.25 Million | 8.4% |
| Inventory | CN¥379.93 Million | 8.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥287.85 Million | 6.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300497 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangxi Fushine Pharmaceutical Co Ltd's current assets represent 33.2% of total assets in 2025, a decrease from 52.2% in 2011.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 15.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 17.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 8.6% of total assets.
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangxi Fushine Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
Jiangxi Fushine Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.22 | 1.00 | 2.10 |
| Quick Ratio | 0.92 | 0.72 | 1.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥279.40 Million | CN¥7.22 Million | CN¥1.25 Billion |
Jiangxi Fushine Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangxi Fushine Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.41 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | CN¥4.40 Billion |
| Market Capitalization | $1.54 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jiangxi Fushine Pharmaceutical Co Ltd's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jiangxi Fushine Pharmaceutical Co Ltd's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total assets of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.40 Billion ≈ $644.55 Million |
-2.91% |
| 2024-12-31 | CN¥4.54 Billion ≈ $663.89 Million |
-5.86% |
| 2023-12-31 | CN¥4.82 Billion ≈ $705.18 Million |
-4.76% |
| 2022-12-31 | CN¥5.06 Billion ≈ $740.41 Million |
+8.15% |
| 2021-12-31 | CN¥4.68 Billion ≈ $684.61 Million |
+15.64% |
| 2020-12-31 | CN¥4.05 Billion ≈ $592.01 Million |
+55.85% |
| 2019-12-31 | CN¥2.60 Billion ≈ $379.85 Million |
+18.18% |
| 2018-12-31 | CN¥2.20 Billion ≈ $321.41 Million |
+22.75% |
| 2017-12-31 | CN¥1.79 Billion ≈ $261.85 Million |
+27.96% |
| 2016-12-31 | CN¥1.40 Billion ≈ $204.63 Million |
+38.50% |
| 2015-12-31 | CN¥1.01 Billion ≈ $147.74 Million |
+59.67% |
| 2014-12-31 | CN¥632.35 Million ≈ $92.53 Million |
+16.82% |
| 2013-12-31 | CN¥541.31 Million ≈ $79.21 Million |
+13.65% |
| 2012-12-31 | CN¥476.31 Million ≈ $69.70 Million |
+35.10% |
| 2011-12-31 | CN¥352.57 Million ≈ $51.59 Million |
-- |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more